BioCentury
ARTICLE | Emerging Company Profile

Affinia: Optimizing for AAV vector function

Led by AveXis’ Rick Modi and Sean Nolan, gene therapy company Affinia debuts with $60M series A

April 1, 2020 1:13 AM UTC
Updated on Apr 1, 2020 at 9:27 PM UTC

With a $60 million series A round, a pair of gene therapy veterans at the helm and a platform designed by the co-inventor of the AAV9 vector, Affinia Therapeutics is developing gene therapies based on a platform that pinpoints AAV vectors with the best properties for a particular application.

Existing investors F-Prime Capital and New Enterprise Associates joined new investor Atlas Venture to lead the series A round announced on Tuesday. Seed investors Alexandria Venture Investments, Lonza Group Inc. and Partners Innovation Fund also participated in the round...